The successful execution of a first clinical case is often underestimated in its strategic importance. Beyond its immediate clinical objective, the first case represents a critical inflection point that can either accelerate adoption or create long-lasting resistance within an institution. Particularly in complex oncology technologies, where multiple stakeholders and operational steps must converge, even minor misalignments can compromise outcomes. Recognizing and managing this complexity is essential for building sustainable adoption pathways. 

ALS | COSTA 
Strategic Perspectives on Oncology Innovation and Market Development